Zuclopenthixol: Brands, Price & Uses in Bangladesh

Zuclopenthixol is a typical (first-generation) antipsychotic of the thioxanthene class. Its approved and evidence-supported uses differ by formulation and are classified below by strength of evidence.

Established / guideline-supported uses

• Schizophrenia and other psychotic disorders (e.g. paranoid psychosis): Zuclopenthixol tablets and short-acting injection are used for acute exacerbations, particularly when accompanied by agitation, aggression, or hostility.
• Maintenance treatment of schizophrenia: the long-acting depot (decanoate) injectable form of Zuclopenthixol is used for maintenance therapy in patients with chronic psychotic illness, especially where adherence to daily oral treatment is a concern.
• Acute psychomotor agitation associated with psychosis: the short-acting depot preparation ("acuphase") form of Zuclopenthixol provides several days of antipsychotic and sedative effect from a single intramuscular injection, used for rapid control of acute psychotic agitation.

Off-label / historically described use

• Low-dose oral Zuclopenthixol has historically been described for short-term management of severe anxiety or agitation unresponsive to other treatments in some markets; this is not a primary approved indication and is not generally recommended given the availability of better-studied alternatives.

Zuclopenthixol is not approved for the treatment of dementia-related behavioural disturbances in elderly patients (see Precautions and Warnings).

Oral tablets (acute and maintenance treatment)

Short-acting injection ("acuphase") – acute agitated psychosis

50–150 mg of Zuclopenthixol acuphase by deep intramuscular injection; may be repeated after 2–3 days if needed. Treatment with the acuphase form is generally limited to a maximum of around 2 weeks before switching to oral or depot Zuclopenthixol, and the cumulative course dose is typically capped by the prescriber's protocol.

Long-acting depot injection (decanoate) – maintenance therapy

For patients previously stabilised on oral Zuclopenthixol or being converted from another antipsychotic, a test dose of 100 mg of Zuclopenthixol decanoate is often given first. Maintenance doses of 200–500 mg by deep intramuscular injection every 2–4 weeks are typical; some patients require up to 600 mg per week under specialist supervision. Injection volumes greater than 2 mL should be divided between two injection sites (e.g. left and right gluteal muscle).

Renal and hepatic impairment

There are no formally established dose tables for renal or hepatic impairment; because Zuclopenthixol is predominantly hepatically metabolised, patients with hepatic impairment should be started on a lower dose with slower titration and close monitoring. In renal impairment, caution and clinical monitoring are advised. Specialist guidance should be sought in both situations.

Pediatric use

Safety and efficacy of Zuclopenthixol have not been established in children and adolescents; it is not recommended for use in this age group (see Pediatric Uses).

Common side effects of Zuclopenthixol include:

• Sedation/drowsiness
• Extrapyramidal symptoms (tremor, rigidity, akathisia, dystonia)
• Dry mouth
• Orthostatic hypotension, tachycardia, palpitations
• Hyperprolactinemia (which may cause menstrual disturbances, galactorrhea, or sexual dysfunction)
• Weight gain

Serious but less common effects of Zuclopenthixol include:

• Neuroleptic malignant syndrome (fever, severe muscle rigidity, autonomic instability, altered consciousness) – requires immediate medical attention
• Tardive dyskinesia (involuntary, potentially irreversible movements), with risk increasing with duration of Zuclopenthixol use
• QT-interval prolongation and, rarely, ventricular arrhythmia
• Seizures (lowered seizure threshold)
• Agranulocytosis/blood dyscrasias (rare)

With the depot forms of Zuclopenthixol, adverse effects may take longer to appear and longer to resolve after stopping treatment compared with the oral form, because the drug continues to be released from the injection site for days to weeks.